一种新型重组人血小板生成素治疗妊娠期免疫性血小板减少症
本研究纳入31例血小板计数低于30×10^9/L、有出血表现、对糖皮质激素和/或静脉注射免疫球蛋白(IVIG)无效且对血小板输注无效的妊娠期免疫性血小板减少症(ITP)患者,给予重组人血小板生成素(rhTPO)300 U/kg每日一次共14天。23例(74.2%)有效,其中完全反应10例(>100×10^9/L)、反应13例(30-100×10^9/L);出血症状明显改善,耐受性良好,中位随访53周(范围39-68周)婴儿未见先天性疾病或发育迟缓。
要点
- 妊娠期ITP患者接受rhTPO 300 U/kg每日一次共14天,74.2%(23/31)有效。
- 完全反应(血小板>100×10^9/L)10例,反应(30-100×10^9/L)13例。
- 出血症状明显改善,即使无反应者也如此;头晕、乏力、注射部位疼痛各1例。
核心结论
- rhTPO可能是妊娠期ITP患者一种安全有效的治疗选择。
- 本研究为rhTPO及其他血小板生成类药物用于妊娠期ITP管理的进一步研究奠定了基础。
研究设计与样本
- 研究纳入血小板计数低于30×10^9/L、有出血表现、对糖皮质激素和/或IVIG无效且对血小板输注无效的妊娠期ITP患者。
- 31例患者接受rhTPO初始剂量300 U/kg每日一次共14天。
- 研究注册号为NCT02391272。
主要发现
- 23例患者有效(74.2%),包括10例完全反应(血小板>100×10^9/L)和13例反应(血小板30-100×10^9/L)。
- rhTPO似可显著改善出血症状,即使无反应者也如此。
- rhTPO耐受性良好,头晕、乏力、注射部位疼痛各报告1例。
- 中位随访53周(范围39-68周),婴儿未见先天性疾病或发育迟缓。
关键数值与推荐
- 完全反应定义为血小板>100×10^9/L,反应定义为血小板30-100×10^9/L。
- rhTPO初始剂量为300 U/kg每日一次共14天。
临床怎么用
- 原文结论认为rhTPO可能是妊娠期ITP患者一种安全有效的治疗选择。
- 原文指出本研究为rhTPO及其他血小板生成类药物用于妊娠期ITP管理的进一步研究奠定了基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to determine the safety and efficacy of recombinant human thrombopoietin (rhTPO) for the management of immune thrombocytopenia (ITP) during pregnancy. Pregnant patients with ITP were enrolled in the study if they had a platelet count less than 30 × 109/L, were experiencing bleeding manifestations, had failed to respond to corticosteroids and/or intravenous immunoglobulin (IVIG), and had developed refractoriness to platelet transfusion. Thirty-one patients received rhTPO at an initial dose of 300 U/kg once daily for 14 days. Twenty-three patients responded (74.2%), including 10 complete responders (>100 × 109/L) and 13 responders (30-100 × 109/L). It appears that rhTPO ameliorated the bleeding symptoms remarkably, even in the nonresponders. rhTPO was well tolerated. Dizziness, fatigue, and pain at an injection site were reported in 1 patient each. No congenital disease or developmental delays were observed in the infants in a median follow-up of 53 (range, 39-68) weeks. In conclusion, rhTPO is a potentially safe and effective treatment choice for patients with ITP during pregnancy. Our work has paved the way for further study on the clinical application of rhTPO and other thrombopoietic agents for the management of ITP during pregnancy. This study is registered at www.clinicaltrials.gov as NCT02391272.
引用
- Kong Z, Qin P, Xiao S, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017. PMID: 28630121. doi:10.1182/blood-2017-01-761262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。